Thompson Investment Management Inc. Sells 2,786 Shares of Bristol-Myers Squibb (NYSE:BMY)

Thompson Investment Management Inc. decreased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 2.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 99,181 shares of the biopharmaceutical company’s stock after selling 2,786 shares during the quarter. Thompson Investment Management Inc.’s holdings in Bristol-Myers Squibb were worth $6,049,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. LaFleur & Godfrey LLC grew its holdings in shares of Bristol-Myers Squibb by 3.5% in the 4th quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company’s stock valued at $2,463,000 after buying an additional 1,487 shares during the period. Brighton Jones LLC lifted its holdings in Bristol-Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $57,000. Savant Capital LLC increased its holdings in shares of Bristol-Myers Squibb by 1.3% in the fourth quarter. Savant Capital LLC now owns 96,631 shares of the biopharmaceutical company’s stock worth $5,465,000 after acquiring an additional 1,231 shares in the last quarter. Finally, Comprehensive Financial Planning Inc. PA acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth about $34,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction that occurred on Friday, April 25th. The shares were acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Stock Up 1.9%

Shares of NYSE:BMY opened at $49.96 on Wednesday. The business has a 50-day moving average price of $48.97 and a 200 day moving average price of $54.92. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The company has a market capitalization of $101.66 billion, a price-to-earnings ratio of -11.30, a PEG ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same period in the prior year, the firm earned ($4.40) earnings per share. The business’s quarterly revenue was down 5.6% compared to the same quarter last year. Sell-side analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on BMY shares. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Jefferies Financial Group reduced their price objective on Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research report on Wednesday, April 23rd. Argus raised Bristol-Myers Squibb to a “hold” rating in a research report on Friday, April 25th. Piper Sandler started coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 target price on the stock. Finally, UBS Group decreased their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research note on Friday, April 11th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.